Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Disc Medicine Nets $90M Series B Financing

CAMBRIDGE, MA, Disc Medicine, a clinical-stage biotechnology company, announced a $90 million Series B financing.
Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, announced a $90 million Series B financing from a leading syndicate of investors.

The financing was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments. Existing investors also participated in the financing, including Atlas Venture, Novo Holdings and Access Biotechnology.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading